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MigrationGlioblastoma multiforme is highly aggressive and is the most common glial tumor type. Although there have
been advances in treatment, the average survival expectancy is 12–15 months. Several genes have been
shown to inﬂuence glioblastoma progression. In the present work, we demonstrate that the RhoGTPase
Activating Protein 21 (ARHGAP21) is expressed in the nuclear and perinuclear regions of several cell lines. In
T98G and U138MG, glioblastoma derived cell lines, ARHGAP21 interacts with the C-terminal region of Focal
Adhesion Kinase (FAK). ARHGAP21 depletion by shRNAi in T98G cells alters cellular morphology and
increases: FAK phosphorylation states and activation of downstream signaling; the activity state of Cdc42;
the production of metalloproteinase 2 (MMP-2) and cell migration rates. These modiﬁcations were found to
be mainly due to the loss of ARHGAP21 action on FAK and, consequently, the activation of downstream
effectors. These results suggest not only that ARHGAP21 might act as a tumor suppressor gene, but also
indicate that ARHGAP21 might be a master regulator of migration having a crucial role in controlling the
progression of different tumor types.© 2009 Elsevier B.V. All rights reserved.1. Introduction
The Rho-family GTPases are the main regulators of actin
cytoskeleton dynamics [1]. These molecules cycle between an active
GTP-bound form and an inactive GDP-bound form. This cycle is
controlled byguanine nucleotide exchange factors (RhoGEFs), positive
regulators that promote the release of bound GDP and facilitate GTP
binding [2], guanine nucleotide dissociation inhibitors (RhoGDIs),
which sequester the GDP-bound form of RhoGTPase and may also
regulate their intracellular localization [3], and by GTPase activating
proteins (RhoGAPs), negative regulators that increase the intrinsic
GTPase activity of the RhoGTPase [4].
Currently, over 70 RhoGAP proteins encoded by the human
genome have been described [5]. An important member is ARHGAP21,
a protein identiﬁed in a Brazilian cancer EST database that contains, in
addition to its RhoGAP domain, a Pleckstrin Homology domain (PH)
and a PSD-95/Discs-large/ZO-1 (PDZ) domain [6]. As PDZ domains are
commonly conserved protein–protein interaction domains found in
organisms ranging from bacteria to humans [7] and as the modular
structures of GAPs are important for their interaction with otherMedicine, Hematology and
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than the negative control of RhoGTPases. In fact, recently, ARHGAP21
was shown not only to have preferential GAP activity over Cdc42, but
also to bind to ARF1-GTPase to control vesicular trafﬁcking on Golgi
membranes, and to interact with α-catenin, recruiting this protein to
endothelial sites of bacterial invasion [8]. Thus, ARHGAP21 is being
characterized as a controller of actin cytoskeleton dynamics.
Glioblastoma multiforme (GBM; astrocytoma WHO grade 4) is a
highly malignant brain tumor that accounts for over 50% of all glial
tumor types, with a median survival rate of under 1 year [9]. Current
treatments of these tumors include surgery followed by radiation and
chemotherapy with highly toxic, non-speciﬁc agents [10]. The key
contributor to treatment failure is the high capacity of malignant
gliomas to inﬁltrate and invade adjacent brain structures, which
renders surgical removal difﬁcult [11]. Therefore, if novel targets for
therapy design are to be identiﬁed, a better understanding of the
molecular mechanisms that control glioblastoma cell migration is
imperative.
Given the importance of RhoGAPs in inhibiting actin dynamics and
the high levels of ARHGAP21 in the normal human brain [6], we
postulated that ARHGAP21 might play an important role in glioblas-
toma cell migration. In agreement with our hypothesis, we found that
ARHGAP21 interacts with the Focal Adhesion Kinase (FAK) in
glioblastoma cell lines (T98G and U138MG), and that its knockdown
in T98G cells leads to increased cellular migratory properties;
furthermore, the pathways leading this event are mediated by FAK
and Cdc42 increased activity states. Our results identify ARHGAP21 as
807C.L. Bigarella et al. / Biochimica et Biophysica Acta 1793 (2009) 806–816a novel inhibitor of glioblastoma cell migration and suggest that
ARHGAP21 might function as a metastasis suppressor in glioblastoma
multiforme.
2. Materials and methods
2.1. Nomenclature
Gene symbols used in this article follow the recommendations of
the HUGO Gene Nomenclature Committee [12].
2.2. Reagents and antibodies
Polyclonal antibody against ARHGAP21 was generated against a
synthetic peptide (KSDSGSLGDAKNEKE), corresponding to residues
1856–1870 of the human protein and afﬁnity puriﬁed by Bethyl
Laboratories, Inc. (Montgomery, Texas). Rabbit polyclonal antibodies
against FAK, c-Src, p130CAS and Histone-H1, monoclonal anti-Cdc42,
and goat polyclonal antibody against P-FAK Tyr925 was purchased
from Santa Cruz Biotechnology (Santa Cruz, CA). Rabbit polyclonal
antibodies against P-Src Tyr418 and P-FAK Tyr397 were purchased
from Biosource (Bethesda, MD). Phalloidin-TRITC was purchased from
Sigma (St Louis, MO). Anti-transferrin receptor (Tr) is from Zymed
Laboratories Inc. (San Francisco, CA). AlexaFluor® 488, AlexaFluor®
633 and AlexaFluor® 555 conjugated secondary antibodies and
ProLong® Gold antifade reagent with DAPI were from Molecular
Probes (Eugene, OR). Enhanced chemiluminescence reagents were
obtained from GE Health Care (Buckinghamshire, UK). All other
reagent grade chemicals were obtained from Sigma.
2.3. Cell culture
The human glioblastoma derived cell lines, A172, T98G and
U138MG, and the cervical carcinoma cell line HeLa were obtained
from the American Type Culture Collection (ATCC). The short-term
culture of normal human ﬁbroblasts was established from the skin of a
mammary reduction surgery, in accordance with the Helsinki
Declaration Guideline of 1975 (reviewed in 1983) at Dr. Gláucia
Santelli Laboratory (ICB, University of São Paulo, São Paulo, Brazil). All
cell lines were maintained in Dulbecco's modiﬁed Eagle's medium
(DMEM) with 4 mM L-glutamine, adjusted to contain 1.5 g/L sodium
bicarbonate and 4.5 g/L glucose, supplemented with 10% fetal bovine
serum (Gibco-Invitrogen) in an atmosphere of 5% CO2–air at 37 °C.
2.4. Cell fractionation
A172, T98G and HeLa cells were cultivated until reaching the
desired conﬂuence and then collected in buffer A (10 mM Hepes pH
7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, sodium orthovanadate,
aprotinin and PMSF). Cell pellet was ressuspended in buffer A plus
0.1% NP-40 and homogenized with an insulin syringe 20 times for
membrane disruption. Nuclear-, membrane- and cytoplasm fractions
(pellet and supernatant, respectively) were separated by centrifuga-
tion. The supernatants were centrifuged for 1 h at 100,000 ×g to
fractionate membrane (pellet) and cytoplasm fractions. The mem-
brane fraction was ressuspended in buffer A plus 0.1% Triton-X-100
and the nuclei fraction was ressuspended in buffer B (20 mM Hepes,
pH 7.9; 1.5 mM MgCl2; 0.5 mM DTT, 25% glycerol; 0.2 mM EDTA;
0.42 M NaCl; sodium orthovanadate; aprotinin). 100 μg of protein
extract of the cytoplasm fraction and the corresponding percentage of
the other extracts were fractionated in SDS-PAGE.
2.5. Generation of ARHGAP21-knockdown cells
Small hairpin type RNAi oligonucleotides (shRNAi) were designed
using the Ambion inc. web site. The sequences were cloned into theexpression vector, pSilencer 2.1 U6 neo™ (Ambion Inc, Austin, TX),
following themanufacturer's instructions. The shRNAi sequences used
to silence the ARHGAP21 human gene (GenBank accession number
NM-020824) in T98G glioma cell line were sh1: GATCCCGCACGTACC-
TAGTCTGAAGTTCAAGAGACTTCAGACTAGGTACGTGCTTTTTTGGAAA
and sh2: GATCCCGTATTCGGCCATGGAAACATTCAAGAGATGTTTC-
CATGGCCGAATACTTTTTTGGAAA. As a control for shRNAi, we used a
plasmid of the Ambion kit that contained a shRNAi with no homology
to human, mouse or rat genomes. Brieﬂy, T98G cells were transfected
with pSilencer™ plasmid containing the control or ARHGAP21-shRNAi
using Lipofectamine 2000® (Invitrogen Inc, Carlsbad, CA) transfection
reagent, following the manufacturer's instructions. Four hours later,
medium containing 20% FBS was added (to a ﬁnal concentration of
10%); after 24 h, the transfection medium was changed to 10% FBS
DMEM, and 48 h later, the cells were harvested and divided in 100mm
dishes to start clone selection using 500 μg/mL of G418 (Gibco-
Invitrogen Inc, Carslbad, CA).
2.6. Phase contrast imaging
Fixed cell images were acquired with a Nikon Eclipse E600
microscope equipped with light, epiﬂuorescence illumination and a
high-resolution CCD camera (RT Slider, Diagnostic Instruments, Inc.,
Sterling Heights, MI, USA) and a PC running Image-Pro software
(Media Cybernetics, Inc., Silver Spring, MD, USA), using the 200×
objective. Pictures shown are representative of the morphology
changes of all analyzed clones.
2.7. Confocal immunoﬂuorescence microscopy
Confocal imaging was carried out using primary antibodies against
ARHGAP21, Cdc42, FAK and P-FAK Y925 (diluted 1:100) or TRITC-
Phalloidin. Brieﬂy, 2×104 cells were plated on coverslips. Cells were
ﬁxed in 4% paraformaldehyde-PBS for 20 min and then permeabilized
with 0.5% Triton-X-100 in PBS for 10 min. The cells were blocked with
3% skimmed milk-PBS and then incubated with the indicated primary
(overnight, 4 °C) and secondary (1 h, room temperature) antibodies,
and with phalloidin-TRITC (dilution 1:500) for 30 min. Finally,
coverslips were mounted on slides using the ProLong Gold® antifade
reagent and the cells were analyzed by confocal laser scanning in a
LSM 510 (Zeiss, Welwyn Garden City, UK) mounted over an Axioplan
microscope (Zeiss) using 40× or 63× 1.3 NA oil immersion objectives.
In order to compare signals from different stained proteins, the pin-
hole aperture was ﬁxed. FAK and Cdc42 staining reproduced results,
which were found in all analyzed ARHGAP21-inhibited clones. For the
quantiﬁcation of ARHGAP21/FAK colocalization (shown in Fig. 2B), we
used the “colocalization ﬁnder” plug in of ImageJ free image analysis
software (W. Rasband, National Institutes of Health, Bethesda; http://
rsb.info.nih.gov/ij/). And for the quantiﬁcation of Cdc42 displacement
due to ARHGAP21 depletionwe counted howmany T98G NC (n=601),
sh1 (n=477) and sh2 (n=730) cells showed the Cdc42 localization
changes. Data was analysed using Kruskal–Wallis test of the
GraphPad-Prism software.
2.8. Immunoprecipitation and immunoblotting
T98G and ARHGAP21-knockdown cell lysates were prepared in RIPA
buffer containing protease inhibitors, as previously described [13].
Brieﬂy, 500 μg of total T98G cell extracts was incubated overnight with
5 μg of the speciﬁed antibodies or with normal rabbit immunoglobulin
(IgG) as a negative control. The immune complexes were precipitated
with protein-A-sepharose 50% slurry (GE), washed in RIPA buffer to
remove unspeciﬁc proteins that might be bound to the complex, and
then analyzed by 8% SDS-PAGE and immunoblottingwith the antibodies
of interest. Data from immunoprecipitation experiments is representa-
tive of at least three independent experiments.
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pGEX2T, carrying the portion of the FAK amino-terminal domain
(GST-FERM; residues 1 to 400), pGEX2TK, encoding the fusion protein
C-terminal of FAK (GST-C-term; residues 765 to 1,052), and pGEX-KG,
containing the cDNA sequence of the catalytic domain (GST-CAT;
residues 400 to 396), were a kind gift from Jun-Lin Guan from the
Department of Molecular Medicine of Cornell University, Ithaca, NY
(FERM domain), and Michael Schaller from the Department ofFig. 1. Nuclear localization of ARHGAP21. (A) Confocal micrographs of FHN, HeLa, A172 an
(FHN and A172) and 63× (HeLa and T98G) oil immersion objectives. (B) Cell fractionation
heads) localization of ARHGAP21. The efﬁciency of the fractionation was veriﬁed by transfe
membrane, and nuclear localized. C = cytoplasm; M = membrane and N = nuclei. (For int
web version of this article.)Microbiology and Cancer Center of the University of Virginia School
of Medicine (CAT and C-terminal domains). All constructions were
inserted into Escherichia coli BL21 (RIL) Codon Plus and performed as
previously described [14,15], except for minor modiﬁcations. Glu-
tathione beads, conjugated with the three different GST recombinant
proteins, were used for the pulldown assay on T98G cells lysed in GST-
Fish buffer plus protease inhibitors [16]. The pulled down pellets were
resolved in SDS-PAGE gel and the membranes were probed with anti-
ARHGAP21 or anti-Src antibodies.d T98G cell lines displaying ARHGAP21 (green) and F-actin (red) staining using 40×
of HeLa, T98G and A172 cell lines, which conﬁrms the nuclear and perinuclear (arrow
rring receptor (Tr) and Histone H1 blots, which should be, respectively, cytoplasm and
erpretation of the references to colour in this ﬁgure legend, the reader is referred to the
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The activity of Cdc42 was determined by afﬁnity–precipitation
assay. The Cdc42 WASP-binding domain (amino acids 215 to 295)
cloned in pGEX-KG was a kind gift from Dr. David Sacks from Brigham
and Women's Hospital, Boston, and was expressed as previously
described [17]. T98G NC and T98G-ARHGAP21-knockdown cells wereFig. 2. ARHGAP21 interacts with FAK on U138MG and T98G glioblastoma cell lines. (A) Cell
anti-ARHGAP21 or anti-FAK antibodies and the associated proteins were analyzed by immu
(green) and FAK (red) showing colocalization of those proteins in the perinuclear area. Colo
software and showsmerged images of FAK (red) and ARHGAP21 (green), with colocalized pix
below each merged image. The merged panel of the second column has orthogonal projectio
tagged N-terminus or C-terminus portions of ARHGAP21 were immunoprecipitated with ant
both regions of ARHGAP21. (D) Pulldown assay of T98G cell extracts using constructions of FER
immunoprecipitated with normal rabbit-IgG, anti-ARHGAP21 or anti-FAK antibodies and t
Immunoblotting with anti-FAK was used to show that FAK precipitation was successful. IP
Confocal images were taken using the 40× water immersion objective. Max colocal. = areas
terminus domain; CAT = catalytic domain and C-TERM = C-terminus domain. (For interpre
version of this article.)lysed in GST-Fish buffer (10% glycerol, 50 mM Tris pH 7.4, 100 mM
NaCl, 1% NP-40, 2 mM MgCl2, 10 μg/mL aprotinin, 1 mM phenyl-
methylsulfonyl ﬂuoride, 1 mM sodium orthovanadate and 1 μg/mL
leupeptin). Five-hundred μg of total proteins were incubated with
100 μg GST-WBD beads, for 90 min at 4 °C. Cdc42-WBD complexes
were fractionated in SDS-PAGE and membranes were probed with
anti-Cdc42 monoclonal antibody. Cdc42-GTP (Cdc42-WBD) waslysates from U138MG and T98G were co-immunoprecipitated with normal rabbit-IgG,
noblotting with the same antibodies. (B) Immunoﬂuorescence staining of ARHGAP21
calization analysis was performed with the Colocalization Finder plug in of ImageJ NIH
els inwhite. Pearson's correlation coefﬁcient (Rr) and Overlap coefﬁcient (R) are shown
ns of the overlapping proteins. (C) Two clones of T98G cells stable transfected with V5-
i-V5 and immunoblotted with anti-FAK. Results demonstrate the interaction of FAK with
M, Catalytic (CAT) and C-terminal (C-TERM) domains of FAK. (E) T98G cell extracts were
he interaction with active FAK was analyzed by immunoblotting with anti-FAKY925.
= immunoprecipitation, IgG = normal rabbit immunoglobulin, IB = immunoblotting.
of maximal colocalization between FAK and ARHGAP21. FAK GST-constructs: FERM = N-
tation of the references to colour in this ﬁgure legend, the reader is referred to the web
810 C.L. Bigarella et al. / Biochimica et Biophysica Acta 1793 (2009) 806–816compared to total Cdc42 content of cell extracts. Activity assay was
performedwith clones obtained from three independent transfections
and all showed increased Cdc42-GTP.
2.11. Migration assay
T98G NC and ARHGAP21-knockdown cells were submitted to
migration assays in Costar transwells (8 μM pore membrane). Brieﬂy,
polycarbonate membranes were incubated with 1 mg/mL of poly-L-
lysine in DMEM for 2 h at 37 °C and then washed with dd-water.
Synchronized cells (grown for 24 h in the absence of serum) were
harvested, counted and 5×104 cells were plated per membrane.
Medium containing 10% FBS and mediumwithout serum in the lower
compartment of the transwells were used as chemo-attractant and
control, respectively. After 48 h, cells were ﬁxed in 5% glutaraldehyde-
PBS and stained with 1% toluidine blue [18]. Cells on the upper side of
the membrane were removed with a cotton-swab. The membranes
were dried, the dyewas eluted with 1% SDS and the amount of cells on
the lower side of the membrane (migrated cells) was estimated by its
absorbance at 595 nm, as a function of total cell absorbance
(membranes without upper side cells removed). At least two
independent experiments were performed using triplicates for all
conditions. Wilcoxon Rank Sum Test was used to analyze data from
migration experiments (two independent samples) using the BioEstat
software. Results are shown as mean±SD.
2.12. Gelatin zymography
T98G and ARHGAP21-knockdown cells were plated (1×105 cells/
well) in 12-well plastic plates or in wells prior containing a thin layer
of 5 mg/mL Matrigel™ (BD Biosciences, Bedford, MA). Cells were
grown for 48 h and then the culture medium was replaced by DMEM
without serum. Forty-eight hours later, the mediumwas collected and
clariﬁed by centrifugation and the cells of each well were counted. A
volume of supernatant corresponding to 1×104 cells was applied toFig. 3. ARHGAP21 depletion results inmorphological and cytoskeleton changes. (A) immunob
cells (KD), resulting from the stable transfection of two different shRNAi. Antibodies agains
Representative optical micrographs (200× magniﬁcation) and (C) confocal imaging (40× oil
morphological and cytoskeleton re-organization in T98G-ARHGAP21-knockdown cells (KD c
evidencing F-actin alterations.each lane of a 7.5% SDS-PAGE containing 0.1% gelatin. The gel was then
washed in a Triton-X-100 buffer to remove traces of SDS and then in
water to remove Triton. The gel was incubated in zymography buffer
for 24 h (37 °C). Finally, the gel was left staining in Coomassie-brilliant
blue for 16–18 h and destained for 2 h. Zymography experiments have
been performed with clones obtained in all three independent
transfections and similar results were found.
3. Results
3.1. Subcellular localization of ARHGAP21
ARHGAP21 localizes to the nuclei and perinuclear region of normal
human ﬁbroblasts (FHN), glioblastoma cell lines A172 and T98G and the
cervical carcinoma cell line, HeLa (Fig. 1A), which corroborates previous
work from our lab [19]. In addition, the presence of ARHGAP21 in the
nuclear fraction of all cell lines was also observed in cellular lysates of
A172, T98GandHeLacells,whichwesubmitted to fractionation(Fig.1B).
The presence of ARHGAP21 in the membrane fraction of HeLa cells is
probably due to its presence in perinuclear vesicular compartment that
precipitates togetherwith themembrane fraction (Fig.1A, arrowheads).
The efﬁcacy of the fractionation protocol was checked by subcellular
distribution of the transferrin receptor, a known cytoplasmic and
membrane protein (Tr), and of Histone H1, a known nuclear protein.
The speciﬁcity of ARHGAP21 polyclonal antibody was evaluated by
immunoprecipitation, shRNAi and blotting with the antibody and
rabbit pre-immune serum (Supplementary material, Sup. Figs. 1A and
B), and immunoﬂuorescence negative controls were carried out using
rabbit pre-immune serum and the respective secondary antibody
(Supplementary material, Sup. Fig. 2B).
3.2. ARHGAP21 interacts with the C-terminal portion of FAK
In order to investigate the involvement of ARHGAP21 in the
integrin-signaling pathway that mediates extracellular matrixlotting of cell lysates fromT98GNC (negative control) and T98G-ARHGAP21-knockdown
t β-actin and α-catenin were used as controls of to show the equal protein loading. (B)
immersion objective) of actin cytoskeleton stained with phalloidin-TRITC, showing the
ells). (D) Pictures of zoomed individual cells are shown in higher magniﬁcation (63×)
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U138MG cell lines of the endogenous ARHGAP21 with several known
cytoskeletal proteins and found the protein to interact with the Focal
Adhesion Kinase (FAK) (Fig. 2A), a master regulator of integrin
signaling known to regulate RhoGAPs [1]. Confocal micrographs
displayed that the interaction between these proteins occur in the
perinuclear region (colocalization zones displayed inyellowandwhite
dots generated by the “Colocalization Finder” plug in from ImageJ
software, Fig. 2B) and quantitatively displays a high overlapping
coefﬁcient. T98G stable transfected clones expressing constructs of
ARHGAP21-V5 tagged N-terminus (#1 and #2) or C-terminus (#2 and
#5) showed that the interaction between ARHGAP21 and FAK can be
mediated by both portions of ARHGAP21 (Fig. 2C), as the overlapping
region of those constructs comprises only 47 amino acids and neither
of the domains [20]. Further conﬁrmation of an ARHGAP21-FAK
complex came from pulldown assays using different FAK constructs
(FAK's N-terminus domain (FERM), catalytic domain (Cat) and the C-
terminus-focal adhesion target domain (C-term)), which mapped
ARHGAP21 speciﬁc binding to the C-terminus of FAK (Fig. 2D). Src
pulldown was used as a positive control, since it is known to interact
with the Tyr 397 of FAK, which is present in the FERM construct.
Similar results were also found in the A172 glioblastoma cell line,
MCF-7 breast carcinoma cell line and rat cardiomyocytes [19].Fig. 4. ARHGAP21 knockdown increases phosphorylation states of FAK and the downstream e
knockdown clones with anti-P-FAK Y397, anti-P-FAK Y925 and anti-P-Src Y418 a
Immunoprecipitation of p130CAS and immunoblotting with anti-P-Tyr; quantitation of t
and showed the increased phosphorylation of p130CAS on ARHGAP21-knockdown clone
knockdown clone (KD cells) in group or isolated, demonstrating the augment in FAK Y925
on T98NC showing empty nuclei and white arrows displaying FAKY925 nuclear accumula
cells. IP = immunoprecipitation, IgG = normal rabbit immunoglobulin, IB = immunoblott
ﬁgure legend, the reader is referred to the web version of this article.)However, immunoprecipitation experiments in T98G cells using
anti-FAK or anti-ARHGAP21 antibodies and blotting with anti-FAK-
Y925 displayed that ARHGAP21 does not interact with FAK when
Tyr925 is phosphorylated (Fig. 2E).
3.3. T98G-ARHGAP21-knockdown cells display altered morphology and
actin cytoskeleton appearance
T98G glioblastoma cells were transfected three times, indepen-
dently, and results herein are representative of all transfections.
Plasmids (pSilencer 2.1 U6 neo® — Ambion) containing short-hairpins
interfering RNA (shRNAi) directed to silence the ARHGAP21 human
gene or control-ones were used. Several stable inhibited clones
(named “#”) were selected. Depletion of ARHGAP21 was demon-
strated in four selected clones that achieved almost total depletion of
ARHGAP21, demonstrated by protein levels (Fig. 3A). As a control of
protein levels, we used β-actin and α-catenin, a known binding
protein of ARHGAP21 [20]. The inhibition triggered morphological
changes, which are similar to an epithelial to mesenchymal transition
(Fig. 3B), and actin cytoskeleton changes from bundled, cortical actin
to a disarranged pattern displaying accumulation of actin in the
perinuclear region and the formation of membrane protrusions (Figs.
3C, zoomed areas and d, higher magniﬁcation of individual cells).ffector, p130CAS. (A) Immunoblotting of T98G NC and four selected inhibited ARHGAP21-
ntibodies, demonstrating the increased phosphorylation of tyrosine sites. (B)
he P-p130CAS content was normalized in relation to the total p130CAS precipitated
s (graphic). (C) Confocal imaging of T98C-NC and of a representative ARHGAP21-
staining and nuclear localization due to ARHGAP21 knockdown (white arrow heads
tion on KD cells). Yellow arrows show regions of membranar FAK on ARHGAP21 KD
ing, NC = T98G negative control. (For interpretation of the references to colour in this
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activity levels and activation of p130CAS downstream signaling
We checked the activity state of FAK and its downstream effectors.
Western blotting, using antibodies that recognize c-Src phosphory-
lated in Tyr 418 and FAK phosphorylated in Tyr 397 or Tyr 925,
demonstrated that, in T98G-ARHGAP21-knockdown clones, c-SrcFig. 5. Depletion of ARHGAP21 results in increased Cdc42-GTP and its altered localization. (A
of Cdc42-GTP, using theWASP-binding domain GST-fusion (GST-WBD), which evidenced hig
accumulation evidencing the increased Cdc42 accumulation in cells where ARHGAP21 have
ARHGAP21-knockdown clone groped or isolated showing the Cdc42 displacement due to A
GraphPad-Prism software. ⁎pb0.01 and ⁎⁎pb0.001.displayed increased phosphorylation, as did FAK phosphorylation in
autocatalytic Tyr397 and in Tyr925, when compared to T98G NC cells
(Fig. 4A). These alterations may occur due to the increased FAK
phosphorylation in Tyr 397, which may increase Src phosphorylation,
which then phosphorylates other sites on FAK, including the Tyr925.
We also examinedwhether the p130CAS phosphorylation pattern is
altered by ARHGAP21 depletion. The levels of phosphorylated p130CAS) T98G NC and T98G-ARHGAP21-knockdown clones were submitted to a pulldown assay
her Cdc42 activity when ARHGAP21was depleted. (B) Quantitation of Cdc42 perinuclear
been depleted (sh1 and sh2). (C) Confocal imaging of T98C-NC and of a representative
RHGAP21 depletion. Statistical analysis were done using the Kruskal–Wallis test of the
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immunoprecipitation assays using an antibody against p130CAS,
followed by immunoblotting with anti-P-Tyr. The amount of phos-
phorylated p130CAS has been quantiﬁed (Fig. 4B, graph) in relation to
total p130CAS precipitated in the assay (p130CAS blot), and the loading
has been controlled by IgG amounts. p130CAS displayed a 2 to 4 fold
increase in tyrosine phosphorylation levels when ARHGAP21 was
depleted (Fig. 4B, graph), indicating that migration pathways down-
stream of FAK are more active due to ARHGAP21 depletion.
Moreover, FAKY925 expression was increased in ARHGAP21-
knockdown cells as demonstrated by immunoﬂuorescence staining
and confocal microscopy of grouped or individual cells (Fig. 4C, white
arrow heads displaying empty nuclei in T98G NC cells). Interestingly,Fig. 6. Depletion of ARHGAP21 results in increased MMP-2 secretion and higher migrati
supernatants, collected after 48 h of growth in serum-free medium. (B) Graphic showing the
T98G-ARHGAP21-knockdown cells cultivated on poly-lysine or Matrigel-coated plates for 48
and T98G-ARHGAP21 knockdown cells were submitted to migration experiments on trans
migration rates from all clones were statistically signiﬁcant (Wilcoxon Rank Sum Test; ⁎pbFAK phosphorylated in Tyr925 was also present in the nuclear
compartment (Fig. 4C, white arrows).
3.5. ARHGAP21 depletion increases Cdc42 activity and alters Cdc42
subcellular distribution
ARHGAP21 is known to have GAP activity against Cdc42 [8] and
RhoA [20]. Thus, we determined the activity state of Cdc42 and RhoA
when ARHGAP21 was depleted. For this purpose, a pulldown assay
was used with constructs comprising the Wiskott–Aldrich syndrome
protein-binding domain for active Cdc42 (GST-WBD) and the
rhotekin-binding domain for active RhoA (GST-WBD). No RhoA
activity was detected in either parental T98G cell or ARHGAP21on rates. (A) Gelatin zymography of T98G NC and T98G-ARHGAP21-knockdown cell
quantitation of MMP-2 pro and active isoforms. (C) Gelatin zymography of T98G NC and
h, showing the increased MMP-2 secretion, due to ARHGAP21 depletion. (D) T98G NC
wells (8 μm pore) for 48 h, and presented increased migration properties. Increased
0.05).
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found mainly in ARHGAP21-depleted cells (Fig. 5A).
Moreover, Cdc42 translocates tomembrane protrusion regions and
to perinuclear area, colocalizing with actin dots in ARHGAP21-
knockdown cells, following F-actin changes (Fig. 5C, yellow arrow
heads and yellow regions in merge frames). The quantiﬁcation of
Cdc42 displacement evidenced that this feature is raised due to
ARHGAP21 depletion (Fig. 5B). Results shown are representative of all
ARHGAP21-depleted clones analyzed.
3.6. ARHGAP21 depletion increases MMP-2 secretion and migration rates
As FAK is known to promote MMP-2 and MMP-9 production when
it's phosphorylated in tyrosines 397 and 925 [21,22], which are hyper-
phosphorylated when ARHGAP21 is depleted, and since Cdc42 activity
has recently been linked to MMP-2 activation [23], we checked the
secretion of gelatinolityc MMPs from ARHGAP21-knockdown cells.
Gelatin zymography experiments [24], using supernatants of T98G NC
and ARHGAP21-knockdown cells cultivated in serum-free medium forFig. 7. Schematic ARHGAP21 action mechanism. ARHGAP21 is a nuclear and perinuclear pro
depletion by shRNAi causes: (1) FAK phosphorylation on Y397 and Y925 that leads to p130C
and ERK as transcription factors that induce mmp-2 gene transcription, and, ultimately, MM
them to be activated by Cdc42-GTP, resulting in increased actin nucleation; (3) Cdc42-GT
protrusions using nascent actin ﬁlaments.48 h, displayed increased MMP-2 secretion and its slightly activation
when ARHGAP21 was depleted (Fig. 6A). Pro-MMP-2 (72KDa form)
and active MMP-2 (64KDa) secretion was increased in all inhibited
clones (Fig. 6A and B, graph). The cultivation of these cell lines in
basement membrane matrix (Matrigel™ BD Bioscience) for 48 h
induces increased MMP-2 secretion in ARHGAP21-knockdown cells in
comparison to the parental T98G-NC cells (Fig. 6B). Since this
condition mimics an activation of ECM-cell signaling, these results
evidenced that ARHGAP21 mediates ECM-cell communication.
As cell movement through tissues has been observed to play a
primary role in cancer progression, we evaluated the migration
capacity of ARHGAP21-depleted cells. Migration assays were carried
out in Costar Transwells, whose membranes were coated with poly-L-
lysine, in triplicate. Cells have been serum starved before the 48 h
migration assays and differential proliferative rates between clones
have been diminished through measuring the absorbance of ﬁlters
with the total content of cells (upper and bottommembrane cells) and
using this to calculate the percentage of migrated cells. Results shown
are means of at least 2 independent experiments. T98G NC cellstein that interacts with FAK in the perinuclear region of glioblastoma cells. ARHGAP21
AS binding and its activation by Src, which, consequently, results in the activation of JNK
P-2 secretion increases; (2) FAK phosphorylation on Y397 liberates Arp2/3 and allows
P interacts with mPar6 and atypical PKCs at the leading edge to develop membrane
815C.L. Bigarella et al. / Biochimica et Biophysica Acta 1793 (2009) 806–816displayed a mean migration rate (mr) of 30.67%±11.22 while sh1
inhibited clones #3 and #15 displayed mr of 62.78±26.09% and mr of
46.4±6.78%, respectively, and sh2 inhibited ones, #2 and #16,
displayed mr of 51.83±7.52% and mr of 77.83±4.07%, respectively
(Fig. 6D). Pictures displayed are examples of stained-ﬁlters of each
clone after the period of migration.
Our results show signiﬁcant differences (pb0.05) between T98G
NC and ARHGAP21-knockdown cells, suggesting that ARHGAP21
might play an important role controlling glioblastoma cell migration.
4. Discussion
In this reportwe showed that ARHGAP21 is localized to the nucleus
and perinuclear region of several cell lines. Recently, our group
characterized ARHGAP21 translocation from the nucleus to the
membrane due to cardiac pressure overload [19]. In contrast to our
data on cardiomyocytes, we found no stimuli leading to ARHGAP21
translocation from the nuclei in glioblastoma cell lines, which we
hypothesize to be due to the malignant character of those cells. Our
results also contrast to data described by Dubois and Chavrier [8] in
which the authors described only Golgi-localized ARHGAP21. We
concluded that the different results obtained by the two research
groups were due to the permeabilization protocol used: their saponin
permeabilization versus our Triton-X-100 protocol (Supplementary
material, Sup.Fig.2A). Indeed in support of our data, Sousa et al. [20]
showed ARHGAP21 nuclear staining in Caco-2 and JEG-3 epithelial cell
lines. ARHGAP21 nuclear function remains unclear however should be
clariﬁed soon.
We also demonstrated, herein, an interaction between ARHGAP21
and the Focal adhesion kinase (FAK) in glioblastoma cell lines (T98G and
U138MG) thatoccurs in theperinuclear region. FAK is known topromote
cell migration through several signaling pathways. One of these
pathways uses the “CAS” (Crk-associated substrate) family of proteins
that include p130CAS. The p130CAS-SH3 domain mediates its association
with the FAK PR2 and PR3 region (proline-rich regions 2 and 3), and this
association promotes its phosphorylation by Src. Phosphorylated
p130CAS recruits Crk adaptor proteins, which results in Rac1, Cdc42 or
JNK activation and ultimately promotes membrane protrusions and cell
migration [25,26]. Therefore, the interaction between ARHGAP21 and
theC-terminal regionof FAKmight inhibit p130CAS association to thePR3
region, consequently blocking FAK phosphorylation by Src and the
activation of downstream signaling (Fig. 7, item 1).
Depletion of ARHGAP21 drastically changes T98G cellular mor-
phology and results in cytoskeleton rearrangement. This was
characterized by loss of cortical actin, accumulation of perinuclear
actin dots, formation of membrane protrusions and by the activation
of Cdc42, in parallel with FAK (Fig. 7, item 3). The perinuclear
accumulation of both actin and Cdc42 probably results from increased
actin nucleation on Golgi membranes, as described by Dubois et al.
[8]. Since Cdc42 activity has been reported to be also dependent
on FAK, as FAK-knockdown reduces its activation and, activation of
p130CAS results in Cdc42 activation [25,26], ARHGAP21 may exert a
dual control over Cdc42: through its GAP activity and by blocking
p130CAS activation, downstream of FAK.
In addition, the action of ARHGAP21 on Cdc42 has previously been
reported to be important in the control of the Arp2/3 complex and the
F-actin dynamics on Golgi membranes [8]. Interestingly, the FAK-
FERM domain binds to the Arp2/3 complex, however FAK Tyr397
phosphorylation triggers dissociation of the dynamic FAK–Arp3
complex and results in activation of Arp3, necessary for developing
cell protrusions [27]. It has been suggested that the Arp2/3-FAK
complex is released when Arp3 is activated by active Cdc42, thus
enabling FAK phosphorylation. Surprisingly, our results corroborate
this hypothesis, as loss of ARHGAP21 increases Cdc42 activity, which is
then able to increase Arp3 activity and, consequently, release it from
FAK leading, ultimately, to the FAK Tyr397 phosphorylation that weobserved (Fig. 7, item 2). Moreover, since the interaction between
ARHGAP21 and FAK occurs in the perinuclear region, we hypothesize
that ARHGAP21 sequesters FAK in this inactive state, as ARHGAP21
depletion increases FAK Y925 phosphorylation and results in its
translocation to the nuclear compartment. Although this translocation
was not expected since FAK nuclear accumulation is not linked to its
kinase activity [28], GFP-FAT construct, in which the Tyr 925 resides,
was shown to accumulate in the nucleus [29] and stress stimuli or
disruption of cell adhesion trigger FAK nuclear accumulation [30].
Thus, as ARHGAP21 depletion changes adherens junctions composi-
tion [20] there is a possibility that, FAK behaves differently in tumor
cells.
Astrocytic brain tumors, of which glioblastoma multiforme is the
most malignant, express high levels of FAK [31]. The invasion of
adjacent brain sites is mediated mainly through the secretion of
matrix metalloproteases (MMPs), a family of enzymes capable of
degrading many components of the extracellular matrix, such as
collagen, ﬁbronectin and proteoglycans [32]. It has been reported that,
in glioblastoma cell lines, angiopoetin-2 induces increased production
of MMP-2 through activation of FAK→p130CAS [33]. Furthermore, FAK
depletion in head and neck squamous carcinoma cells reduces
invasion via downregulation of MMP-2 expression [34]. Given that
depletion of ARHGAP21 induces higher MMP-2 secretion, as seen in
epithelial to mesenchymal transition (EMT), ARHGAP21 might be an
essential modulator of glioblastoma multiforme progression through
action upon Cdc42 and FAK.
Taken together the above results suggest that ARHGAP21 inhibits
glioblastoma cell migration. This inhibition is mediated by (1)
ARHGAP21 negative regulation of Cdc42, (2) of FAK→p130CAS
signaling inactivation, and (3) a decreased secretion of metallopro-
tease-2. Those results not only suggest that ARHGAP21 might control
glioblastoma aggressiveness, but also indicate that ARHGAP21 might
be a master regulator of migration in different tissues and, as such,
have a crucial role in the control of the progression of different tumor
types.
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